For the year ending 2025-12-31, SPRY had -$9,500K decrease in cash & cash equivalents over the period. -$171,205K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenue | 84,278 |
| Total segment operating expenses-Cost Of Goods Sold | 20,423 |
| Total segment operating expenses-Clinical | 5,342 |
| Total segment operating expenses-Development | 5,315 |
| Total segment operating expenses-Medical Affairs | 4,334 |
| Total segment operating expenses-Selling And Marketing Expense | 176,087 |
| Total segment operating expenses-General And Administrative Expense | 29,352 |
| Total segment operating expenses-Share-Based Compensation | 22,095 |
| Total segment operating expenses-Other Expense | 778 |
| Interest income | 10,669 |
| Interest expense | 2,599 |
| Income tax (benefit) expense | -80 |
| Net (loss) income | -171,298 |
| Stock-based compensation expense | 22,095 |
| Provision for inventory reserve | 2,160 |
| Depreciation and amortization expense | 1,367 |
| Accretion on investments, net of amortization | 5,523 |
| Other non-cash items | -337 |
| Accounts receivable | 17,205 |
| Inventories | 21,986 |
| Prepaid expenses and other assets | -656 |
| Accounts payable and accrued liabilities | 18,881 |
| Contract liability | -350 |
| Net cash and cash equivalents (used in) provided by operating activities | -170,866 |
| Purchases of short-term investments, available-for-sale | 242,033 |
| Maturities of short-term investments, available-for-sale | 307,000 |
| Payments of milestone obligations under license agreements | 7,860 |
| Purchases of property and equipment | 339 |
| Net cash and cash equivalents provided by (used in) investing activities | 56,768 |
| Proceeds from term loan, net of issuance costs | 96,257 |
| Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan | 5,681 |
| Proceeds from milestone obligations met under license agreements recognized as an increase to the financing liability | 2,660 |
| Net cash and cash equivalents provided by financing activities | 104,598 |
| Net decrease in cash and cash equivalents | -9,500 |
| Cash and cash equivalents at beginning of period | 50,817 |
| Cash and cash equivalents at end of period | 41,317 |
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)